001, r = 0.4268). After 3 months of preventive therapy, there was an increase in the fraction of foxp3+ Treg, but no differences in markers of activation or apoptosis. In conclusion, there seems to be an increased level of immune activation and Treg in both latent and active TB infection that is only modestly influenced by preventive therapy. Mycobacterium tuberculosis (TB) infection is a major global health problem, especially in the developing world. In 2008, there were an estimated Romidepsin research buy 8.9–9.9 million incident cases and approximately 2 million deaths from TB [1]. In addition, it is estimated that one-third of the world’s population is infected by TB. If the immunological balance between host

and pathogen

is disturbed, reactivation of latent TB infection (LTBI) and development of active disease may occur. Globally, the human immunodeficiency virus (HIV) is the most dominant risk factor for reactivation of LTBI as well as contracting primary TB infection. The cellular immune system plays a pivotal role in the immune defense against TB, and there is a critical balance between anti-TB T cell responses and immune-mediated pathology. TB induces a state of immune activation in the infected host, and an increased expression of activation markers on T cells in blood from patients with active TB has been described [2, 3]. T regulatory cells (Treg) are CD4+ T cells involved in regulation Napabucasin supplier of self-tolerance, autoimmunity and suppression of immune responses during infections [4, 5]. Treg cells were first recognized as CD4+ CD25+ T cells, Ribonucleotide reductase but expression of the intracellular marker forkhead box p3 (foxp3) and low cell-surface expression of the IL-7 receptor α-chain (CD127) have been suggested as more accurate markers [6–8]. However, recent studies have questioned whether these markers represent different populations of Treg [9]. Patients with active TB seem to have higher levels of CD4+CD25high+foxp3+ Treg cells in blood when compared

to both subjects with LTBI and uninfected controls [10–12]. It has been shown that Treg depress T cell-mediated immune responses to protective TB antigens during active TB disease [11]. The level of Treg seems to decrease after 1 month of anti-tuberculous therapy [13]. Dendritic cells (DCs), professional antigen-presenting cells, initiate adaptive immune responses and stimulate induction and expansion of Treg [14]. Studies have shown that DCs serve an important role in the initiation and control of immune responses to TB [15]. Two DC subsets have been characterized in blood based on differences in phenotype markers and function; myeloid dendritic cell (mDC) and plasmacytoid dendritic cell (pDC) [16]. Decreased numbers of both DC subsets have been found in patients with active TB when compared to controls as well as increased pDC levels following successful anti-tuberculous therapy [17].